Information Provided By: 
Fly News Breaks for May 18, 2015
ALDR
May 18, 2015 | 08:29 EDT
After attending the International Headache Congress, Bernstein says that physicians are more upbeat about anti-CGRP treatments for migraines. The firm has become more positive about the outlook for these treatments, and it now believes that Alder's CGRP treatment, ALD403, has a 60% chance of success, up from 50% previously. Bernstein keeps an Outperform rating on the shares.
News For ALDR From the Last 2 Days
There are no results for your query ALDR
